CRISPR Thx in yet another Collaboration, this time for Muscle Dystrophy

10/06/2016 - 3 minutes

CRISPR Therapeutics has struck a deal with Anagenesis Biotechnologies, which has key technology for muscle stem cells. Together, they will tackle muscle disorders – including the rare disease Duchenne Muscular Dystrophy (DMD).

crispr_therapeutics_anagenesis_biotechnologies_muscleCRISPR Therapeutics (Basel, Switzerland) is the European champion of gene editing for health applications, a field that promises to revolutionize therapies – even if it’s in the middle of a patent war.

To bring this therapeutic revolution to reality, CRISPR Therapeutics’ strategy is far from going at it alone. The company has struck some massive deals in the last months. These include the €2.29Bn collaboration with Vertex Pharmaceuticals (US) and the €275M deal with Bayer (Germany).

Now, CRISPR Therapeutics is joining a new collaboration to its stack – with Anagenesis Biotechnologies, a Biotech specialized in muscle disorders.

Based in France but with a strong base in Boston (not unlike CRISPR Therapeutics), Anagenesis developed its therapeutic technology with the support of the French Muscular Dystrophy Association,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member